Pfizer CFO to depart; GSK wins approval for UTI drug

Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact.

Raccontata daendpoints.news